Opitimal dose of plasmid vascular endothelial growth factor for enhancement of angiogenesis in the rat brain ischemia model

Atsushi Katsumata, Kenji Sugiu, Koji Tokunaga, Noboru Kusaka, Kyoichi Watanabe, Ayumi Nishida, Katsunari Namba, Hirofumi Hamada, Hiroyuki Nakashima, Isao Date

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) administration has recently been assessed as a therapeutic strategy for ischemic diseases including brain ischemia because of its angiogenic effect. However, VEGF also causes detrimental adverse effects by increasing vascular permeability. This study examined whether plasmid human VEGF (phVEGF) administration induced angiogenic effects in the rat brain ischemia model caused by permanent ligation of both common carotid arteries, and investigated the occurrence of adverse effects. Administration of various doses (0-200 μg) of phVEGF in the temporal muscle was followed by encephalo-myo-synangiosis. Thirty days after treatment, the numbers and areas of capillaries per field in the extracted brains were analyzed with the National Institutes of Health Image software program. The maximal angiogenic effect occurred with a 100 mg dose of phVEGF in the numbers and areas of capillaries in the VEGF-treated brains. Histological examination showed no apparent adverse effects in the brain parenchyma even at the highest administration dose (200 μg) of phVEGF. The maximal angiogenic effect at the optimal dose of phVEGF can be considered under the threshold to cause serious adverse effects in the rat brain.

Original languageEnglish
Pages (from-to)449-455
Number of pages7
JournalNeurologia Medico-Chirurgica
Volume50
Issue number6
DOIs
Publication statusPublished - Jun 25 2010

Fingerprint

Brain Ischemia
Vascular Endothelial Growth Factor A
Plasmids
Brain
Temporal Muscle
Common Carotid Artery
National Institutes of Health (U.S.)
Capillary Permeability
Ligation
Software

Keywords

  • Angiogenic effect
  • Brain ischemia
  • Indirect vasoreconstruction
  • Rat brain model
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Opitimal dose of plasmid vascular endothelial growth factor for enhancement of angiogenesis in the rat brain ischemia model. / Katsumata, Atsushi; Sugiu, Kenji; Tokunaga, Koji; Kusaka, Noboru; Watanabe, Kyoichi; Nishida, Ayumi; Namba, Katsunari; Hamada, Hirofumi; Nakashima, Hiroyuki; Date, Isao.

In: Neurologia Medico-Chirurgica, Vol. 50, No. 6, 25.06.2010, p. 449-455.

Research output: Contribution to journalArticle

Katsumata, A, Sugiu, K, Tokunaga, K, Kusaka, N, Watanabe, K, Nishida, A, Namba, K, Hamada, H, Nakashima, H & Date, I 2010, 'Opitimal dose of plasmid vascular endothelial growth factor for enhancement of angiogenesis in the rat brain ischemia model', Neurologia Medico-Chirurgica, vol. 50, no. 6, pp. 449-455. https://doi.org/10.2176/nmc.50.449
Katsumata, Atsushi ; Sugiu, Kenji ; Tokunaga, Koji ; Kusaka, Noboru ; Watanabe, Kyoichi ; Nishida, Ayumi ; Namba, Katsunari ; Hamada, Hirofumi ; Nakashima, Hiroyuki ; Date, Isao. / Opitimal dose of plasmid vascular endothelial growth factor for enhancement of angiogenesis in the rat brain ischemia model. In: Neurologia Medico-Chirurgica. 2010 ; Vol. 50, No. 6. pp. 449-455.
@article{b94cbd874298421a828e780264c327b0,
title = "Opitimal dose of plasmid vascular endothelial growth factor for enhancement of angiogenesis in the rat brain ischemia model",
abstract = "Vascular endothelial growth factor (VEGF) administration has recently been assessed as a therapeutic strategy for ischemic diseases including brain ischemia because of its angiogenic effect. However, VEGF also causes detrimental adverse effects by increasing vascular permeability. This study examined whether plasmid human VEGF (phVEGF) administration induced angiogenic effects in the rat brain ischemia model caused by permanent ligation of both common carotid arteries, and investigated the occurrence of adverse effects. Administration of various doses (0-200 μg) of phVEGF in the temporal muscle was followed by encephalo-myo-synangiosis. Thirty days after treatment, the numbers and areas of capillaries per field in the extracted brains were analyzed with the National Institutes of Health Image software program. The maximal angiogenic effect occurred with a 100 mg dose of phVEGF in the numbers and areas of capillaries in the VEGF-treated brains. Histological examination showed no apparent adverse effects in the brain parenchyma even at the highest administration dose (200 μg) of phVEGF. The maximal angiogenic effect at the optimal dose of phVEGF can be considered under the threshold to cause serious adverse effects in the rat brain.",
keywords = "Angiogenic effect, Brain ischemia, Indirect vasoreconstruction, Rat brain model, Vascular endothelial growth factor",
author = "Atsushi Katsumata and Kenji Sugiu and Koji Tokunaga and Noboru Kusaka and Kyoichi Watanabe and Ayumi Nishida and Katsunari Namba and Hirofumi Hamada and Hiroyuki Nakashima and Isao Date",
year = "2010",
month = "6",
day = "25",
doi = "10.2176/nmc.50.449",
language = "English",
volume = "50",
pages = "449--455",
journal = "Neurologia Medico-Chirurgica",
issn = "0470-8105",
publisher = "Japan Neurosurgical Society",
number = "6",

}

TY - JOUR

T1 - Opitimal dose of plasmid vascular endothelial growth factor for enhancement of angiogenesis in the rat brain ischemia model

AU - Katsumata, Atsushi

AU - Sugiu, Kenji

AU - Tokunaga, Koji

AU - Kusaka, Noboru

AU - Watanabe, Kyoichi

AU - Nishida, Ayumi

AU - Namba, Katsunari

AU - Hamada, Hirofumi

AU - Nakashima, Hiroyuki

AU - Date, Isao

PY - 2010/6/25

Y1 - 2010/6/25

N2 - Vascular endothelial growth factor (VEGF) administration has recently been assessed as a therapeutic strategy for ischemic diseases including brain ischemia because of its angiogenic effect. However, VEGF also causes detrimental adverse effects by increasing vascular permeability. This study examined whether plasmid human VEGF (phVEGF) administration induced angiogenic effects in the rat brain ischemia model caused by permanent ligation of both common carotid arteries, and investigated the occurrence of adverse effects. Administration of various doses (0-200 μg) of phVEGF in the temporal muscle was followed by encephalo-myo-synangiosis. Thirty days after treatment, the numbers and areas of capillaries per field in the extracted brains were analyzed with the National Institutes of Health Image software program. The maximal angiogenic effect occurred with a 100 mg dose of phVEGF in the numbers and areas of capillaries in the VEGF-treated brains. Histological examination showed no apparent adverse effects in the brain parenchyma even at the highest administration dose (200 μg) of phVEGF. The maximal angiogenic effect at the optimal dose of phVEGF can be considered under the threshold to cause serious adverse effects in the rat brain.

AB - Vascular endothelial growth factor (VEGF) administration has recently been assessed as a therapeutic strategy for ischemic diseases including brain ischemia because of its angiogenic effect. However, VEGF also causes detrimental adverse effects by increasing vascular permeability. This study examined whether plasmid human VEGF (phVEGF) administration induced angiogenic effects in the rat brain ischemia model caused by permanent ligation of both common carotid arteries, and investigated the occurrence of adverse effects. Administration of various doses (0-200 μg) of phVEGF in the temporal muscle was followed by encephalo-myo-synangiosis. Thirty days after treatment, the numbers and areas of capillaries per field in the extracted brains were analyzed with the National Institutes of Health Image software program. The maximal angiogenic effect occurred with a 100 mg dose of phVEGF in the numbers and areas of capillaries in the VEGF-treated brains. Histological examination showed no apparent adverse effects in the brain parenchyma even at the highest administration dose (200 μg) of phVEGF. The maximal angiogenic effect at the optimal dose of phVEGF can be considered under the threshold to cause serious adverse effects in the rat brain.

KW - Angiogenic effect

KW - Brain ischemia

KW - Indirect vasoreconstruction

KW - Rat brain model

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=77954501335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954501335&partnerID=8YFLogxK

U2 - 10.2176/nmc.50.449

DO - 10.2176/nmc.50.449

M3 - Article

C2 - 20587967

AN - SCOPUS:77954501335

VL - 50

SP - 449

EP - 455

JO - Neurologia Medico-Chirurgica

JF - Neurologia Medico-Chirurgica

SN - 0470-8105

IS - 6

ER -